Diabetes patients have aberrant insulin metabolic signaling, which reduces insulin-stimulated cardiac nitric oxide (NO) generation and endothelial nitric oxide synthase (eNOS) activity while increasing cardiomyocyte intracellular Ca2+/Ca2+ sensitivity and decreasing sarcoplasmic Ca2+ absorption. The gene discussed is INS; the disease is diabetes mellitus.